Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta‐analysis

Abstract

AbstractBackgroundContemporary dual antiplatelet therapy (DAPT) strategies, such as short‐term DAPT or de‐escalation of DAPT, have emerged as attractive strategies to treat patients with acute coronary syndrome (ACS). However, it remains uncertain whether they are suitable for elderly patients.MethodsPubMed, Embase, and Cochrane CENTRAL databases were searched in September 2022. Randomized controlled trials (RCTs) investigating DAPT strategies, including standard (12 months), short‐term, uniform de‐escalation, and guided‐selection strategies for elderly patients with ACS (age ≥ 65 years) were identified, and a network meta‐analysis was conducted. The primary endpoint was the net clinical benefit outcome, a composite of major adverse cardiovascular events (MACEs: cardiovascular death, myocardial infarction, or stroke) and clinically relevant bleeding (equivalent to bleeding of at least type 2 according to the Bleeding Academic Research Consortium). The secondary outcomes were MACE and major bleeding.ResultsSixteen RCTs with a combined total of 47,911 patients were included. The uniform de‐escalation strategy was associated with an improved net clinical benefit compared with DAPT using potent P2Y12 inhibitors. The short‐term DAPT strategy was associated with reduced risks of the primary outcome and major bleeding compared with DAPT using potent P2Y12 inhibitors, however, it was ranked as the least effective strategy for MACE compared with other DAPT strategies.ConclusionsUniform de‐escalation and short‐term DAPT strategies may be advantageous for elderly patients, but need to be tailored based on individual bleeding and ischemic risks. Further RCTs of contemporary DAPT strategies specifically designed for elderly patients are warranted to confirm the findings of the present study.